ClinicalTrials.gg
Not yet recruitingNCT07668401AMAZE 13Updated Aug 24, 2026

AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight

A Phase 3 interventional study of Zenagamtide and Placebo ( matched to Zenagamtide) in Obesity and Overweight, sponsored by Novo Nordisk A/S. Not yet recruiting at 44 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies testing zenagamtide in Obesity — 17 open to participants now, 20 under way, 14 of them phase 3. zenagamtide · Obesity.

Planned enrollment
9th of 24
400 · median 360
Started
2027
the only one that year
Phase 3
14 of 24
11 open now
Primary completion
2029-01
later than 15 of 19 live
Registered
16th of 24
by date
Lead sponsor
24 of 24
Novo Nordisk A/S

Among the 24 studies testing zenagamtide in Obesity, this one is the 9th largest by planned enrollment, is the only one that started in 2027, is one of 14 in phase 3, reaches primary completion later than 15 of the 19 other live ones, and was the 16th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

17 of the 24 studies testing zenagamtide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About zenagamtide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing zenagamtide in Obesity, or all of them as a file.
02

Study summary

The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide (the treatment being tested) or placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.

03

Conditions studied

  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female (sex assigned at birth, inclusive of all gender identities).
  • Age 18 years or above at the time of signing the

Exclusion criteria

Exclusion Criteria:

  • (HbA1c) ≥ 6.5% (48 mmol/mol) as measured by the central laboratory at screening.
  • History of type 1 or type 2 diabetes mellitus.
  • Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Zenagamtide

    Participants will be randomized to receive 1 out of 3 different dose levels subcutaneously once weekly.

    Drug: Zenagamtide

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to Zenagamtide subcutaneously once weekly.

    Drug: Placebo ( matched to Zenagamtide)

Interventions

  • Zenagamtide will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

  • DrugPlacebo ( matched to Zenagamtide)

    Placebo matched to Zenagamtide will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

06

What researchers measure

Primary outcomes

  1. Relative change in body weight

    Measured as percentage of body weight.

    Time frame: From baseline (week 0) to week 80

Secondary outcomes

  1. Change in waist circumference

    Measured as centimetre (cm).

    Time frame: From baseline (week 0) to week 80

07

Study locations

44 sites
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 24 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2026
First posted
Jun 25, 2026
StartEst.
Jan 7, 2027
Primary completionEst.
Jan 11, 2029
CompletionEst.
Jan 11, 2029
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07668401
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jun 25, 2026
Start date
Jan 7, 2027 (estimated)
Primary completion
Jan 11, 2029 (estimated)
Completion
Jan 11, 2029 (estimated)
Last update
Aug 24, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zenagamtide

Start the discussion